551 related articles for article (PubMed ID: 27372303)
21. Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer.
Santarpia L; El-Naggar AK; Cote GJ; Myers JN; Sherman SI
J Clin Endocrinol Metab; 2008 Jan; 93(1):278-84. PubMed ID: 17989125
[TBL] [Abstract][Full Text] [Related]
22. Anaplastic Thyroid Carcinoma: Current Issues in Genomics and Therapeutics.
Abe I; Lam AK
Curr Oncol Rep; 2021 Feb; 23(3):31. PubMed ID: 33582932
[TBL] [Abstract][Full Text] [Related]
23. Genomic Profiling of Aggressive Thyroid Cancer in Association With its Clinicopathological Characteristics.
Kim JH; Jeong JY; Seo AN; Park NJ; Kim M; Park JY
In Vivo; 2022; 36(1):111-120. PubMed ID: 34972706
[TBL] [Abstract][Full Text] [Related]
24. Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer.
Shi X; Liu R; Qu S; Zhu G; Bishop J; Liu X; Sun H; Shan Z; Wang E; Luo Y; Yang X; Zhao J; Du J; El-Naggar AK; Teng W; Xing M
J Clin Endocrinol Metab; 2015 Apr; 100(4):E632-7. PubMed ID: 25584719
[TBL] [Abstract][Full Text] [Related]
25. Mechanistic Insights of Thyroid Cancer Progression.
Leandro-García LJ; Landa I
Endocrinology; 2023 Aug; 164(9):. PubMed ID: 37503738
[TBL] [Abstract][Full Text] [Related]
26. Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing.
Kunstman JW; Juhlin CC; Goh G; Brown TC; Stenman A; Healy JM; Rubinstein JC; Choi M; Kiss N; Nelson-Williams C; Mane S; Rimm DL; Prasad ML; Höög A; Zedenius J; Larsson C; Korah R; Lifton RP; Carling T
Hum Mol Genet; 2015 Apr; 24(8):2318-29. PubMed ID: 25576899
[TBL] [Abstract][Full Text] [Related]
27. Anaplastic and poorly differentiated thyroid carcinomas: genetic evidence of high-grade transformation from differentiated thyroid carcinoma.
Gu H; Wang J; Ran W; Li G; Hu S; Zhao H; Wang X; Wang J
J Pathol Clin Res; 2024 Mar; 10(2):e356. PubMed ID: 38602501
[TBL] [Abstract][Full Text] [Related]
28. The role of EIF1AX in thyroid cancer tumourigenesis and progression.
Simões-Pereira J; Moura MM; Marques IJ; Rito M; Cabrera RA; Leite V; Cavaco BM
J Endocrinol Invest; 2019 Mar; 42(3):313-318. PubMed ID: 29968046
[TBL] [Abstract][Full Text] [Related]
29. Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma.
Nikitski AV; Rominski SL; Condello V; Kaya C; Wankhede M; Panebianco F; Yang H; Altschuler DL; Nikiforov YE
Thyroid; 2019 Oct; 29(10):1425-1437. PubMed ID: 31298630
[No Abstract] [Full Text] [Related]
30. DICER1 Mutations Do Not Always Indicate Dismal Prognosis in Pediatric Poorly Differentiated Thyroid Carcinomas.
Yegen G; Altay AY; Yılmaz İ; İşcan Y; Sormaz İC; Aksakal N; Önder S; Mete Ö
Endocr Pathol; 2023 Sep; 34(3):279-286. PubMed ID: 37574466
[TBL] [Abstract][Full Text] [Related]
31. Whole-genome sequencing of synchronous thyroid carcinomas identifies aberrant DNA repair in thyroid cancer dedifferentiation.
Paulsson JO; Backman S; Wang N; Stenman A; Crona J; Thutkawkorapin J; Ghaderi M; Tham E; Stålberg P; Zedenius J; Juhlin CC
J Pathol; 2020 Feb; 250(2):183-194. PubMed ID: 31621921
[TBL] [Abstract][Full Text] [Related]
32. Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis.
Charles RP; Silva J; Iezza G; Phillips WA; McMahon M
Mol Cancer Res; 2014 Jul; 12(7):979-86. PubMed ID: 24770869
[TBL] [Abstract][Full Text] [Related]
33. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
34. Molecular alterations of coexisting thyroid papillary carcinoma and anaplastic carcinoma: identification of TERT mutation as an independent risk factor for transformation.
Oishi N; Kondo T; Ebina A; Sato Y; Akaishi J; Hino R; Yamamoto N; Mochizuki K; Nakazawa T; Yokomichi H; Ito K; Ishikawa Y; Katoh R
Mod Pathol; 2017 Nov; 30(11):1527-1537. PubMed ID: 28731042
[TBL] [Abstract][Full Text] [Related]
35. Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations.
Smith N; Nucera C
J Clin Endocrinol Metab; 2015 Jan; 100(1):35-42. PubMed ID: 25347569
[TBL] [Abstract][Full Text] [Related]
36. Molecular Markers Involved in Tumorigenesis of Thyroid Carcinoma: Focus on Aggressive Histotypes.
Penna GC; Vaisman F; Vaisman M; Sobrinho-Simões M; Soares P
Cytogenet Genome Res; 2016; 150(3-4):194-207. PubMed ID: 28231576
[TBL] [Abstract][Full Text] [Related]
37. BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
Costa AM; Herrero A; Fresno MF; Heymann J; Alvarez JA; Cameselle-Teijeiro J; García-Rostán G
Clin Endocrinol (Oxf); 2008 Apr; 68(4):618-34. PubMed ID: 18070147
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic modifications in poorly differentiated and anaplastic thyroid cancer.
Sasanakietkul T; Murtha TD; Javid M; Korah R; Carling T
Mol Cell Endocrinol; 2018 Jul; 469():23-37. PubMed ID: 28552796
[TBL] [Abstract][Full Text] [Related]
39. Mutations of genes including DNMT3A detected by next-generation sequencing in thyroid cancer.
Guo LC; Zhu WD; Ma XY; Ni H; Zhong EJ; Shao YW; Yu J; Gu DM; Ji SD; Xu HD; Ji C; Yang JM; Zhang Y
Cancer Biol Ther; 2019; 20(3):240-246. PubMed ID: 30252567
[TBL] [Abstract][Full Text] [Related]
40. Clinical Utility of Circulating Cell-Free DNA Mutations in Anaplastic Thyroid Carcinoma.
Qin Y; Wang JR; Wang Y; Iyer P; Cote GJ; Busaidy NL; Dadu R; Zafereo M; Williams MD; Ferrarotto R; Gunn GB; Wei P; Patel K; Hofmann MC; Cabanillas ME
Thyroid; 2021 Aug; 31(8):1235-1243. PubMed ID: 33599171
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
